Literature DB >> 6029825

Method for determining antineuraminidase activity.

R B Wagner, B A Steinberg, I Ruchman.   

Abstract

A test was developed to screen drugs for antineuraminidase (influenza sialidase) activity in vitro. Neuraminidase prepared from Vibrio cholerae was added to a substrate containing ganglioside, prepared from calf brain. Sialic acid is a split product in the reaction. The presence of sialic acid was detected colorimetrically by use of Warren's Thiobarbituric Acid Assay after drugs had been added to inhibit the action of neuraminidase on the calf brain substrate.

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6029825      PMCID： PMC546885          DOI： 10.1128/am.15.2.239-242.1967

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN： 0003-6919


  7 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  Studies on the interactions of poliomyelitis virus, antibody, and host cells in tissue culture system.

Authors:  B MANDEL
Journal:  Virology       Date:  1958-10       Impact factor: 3.616

3.  The fixation of tetanus toxin by ganglioside.

Authors:  W E VAN HEYNINGEN; P A MILLER
Journal:  J Gen Microbiol       Date:  1961-01

4.  Serologic studies of the neuraminidases of Vibrio cholerae, Diplococcus pneumoniae and influenza virus.

Authors:  M A MADOFF; E H EYLAR; L WEINSTEIN
Journal:  J Immunol       Date:  1960-12       Impact factor: 5.422

5.  Production of influenza A virus in the cells of the allantois.

Authors:  H J CAIRNS; P J MASON
Journal:  J Immunol       Date:  1953-07       Impact factor: 5.422

6.  Interactions between Newcastle disease virus (NDV), antibody and cell.

Authors:  H RUBIN
Journal:  Virology       Date:  1957-12       Impact factor: 3.616

7.  Growth characteristics of influenza virus; biochemical differentiation of stages of development.

Authors:  W W ACKERMANN; H F MAASSAB
Journal:  J Exp Med       Date:  1954-10-01       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.